Medication info
Valsartan Tablets 80 mg (Valsartan)

Valsartan Tablets 80 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Hankook Hutex Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201702206 · Approved 2017.04.28 · Insurance code 649103470

Summary

Main use
Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg per dose twice daily. Over the following several weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or greater. Do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
1. Essential hypertension 6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Hankook Hutex Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medication is used to treat essential hypertension and is effective in heart failure patients who are intolerant to ACE inhibitors. Additionally, it helps reduce the risk of mortality in stable myocardial infarction patients accompanied by left ventricular failure or systolic dysfunction, as assessed by symptoms or radiological findings. It is used for hypertension control, improvement of heart failure symptoms, and increased survival after myocardial infarction.

How to take

Adult dose

1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg per dose twice daily. Over the following several weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or greater. Do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

1. Essential hypertension 6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This drug can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; therefore, it must be discontinued immediately upon confirmation of pregnancy. It is unsafe to use this drug in pregnant or potentially pregnant women and breast-feeding mothers. It should not be administered to patients with severe liver impairment, severe kidney disease, or a history of certain angioedema. Elderly patients, those with high potassium levels, and patients with moderate liver impairment should use this drug with extra caution. During treatment, there is a risk of sudden drops in blood pressure causing dizziness or fainting, so treatment should start with a low dose and the patient's condition should be carefully monitored. Patients with weak kidney function, heart failure, or those taking diuretics should have their blood pressure, kidney function, and electrolyte levels checked regularly. This drug may interact with other antihypertensive agents or certain diuretics and potassium-sparing diuretics, so consulting a doctor or pharmacist is necessary. Any unusual symptoms such as muscle pain, rash, severe dizziness, or difficulty breathing should be reported to a healthcare professional immediately. Safety and effectiveness in children and teenagers under 18 years have not been sufficiently established, so its use is not recommended. In case of overdose, symptoms such as hypotension, decreased consciousness, or shock may occur, requiring immediate emergency care. This medication should be stored out of reach of children and not transferred to another container.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container, protected from air and moisture, and kept in a cool place below 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.